The partnership between Synthgene Bio, BIORON, and Bion2 represents a major step toward global expansion, enhancing access to key resources for mRNA and oligo research and manufacturing in Eastern Europe. FOR IMMEDIATE RELEASE Gaithersburg, MD, USA and Römerberg,...
Collaboration expands Areterna’s reach in Europe and strengthens Biomay’s mRNA CDMO offerings. Gaithersburg, MD and Vienna, Austria (September 18, 2024) — Areterna LLC, a company with a mission to democratize mRNA products by supplying low-cost GMP raw materials,...
Synthgene Biotechnology, Areterna’s parent company, has been a leading producer of GMP-grade cap analogs, NTPs, and modified NTPs for several years, establishing a strong reputation for quality and reliability in the industry. Our raw materials play a crucial...
Recently, Synthgene Biotech (hereinafter referred to as “Synthgene”), Areterna’s parent company, received a confirmation letter from the United States Food and Drug Administration (FDA) for one of our core mRNA raw material products – CAP5 – which have...
FOR IMMEDIATE RELEASE Gaithersburg, MD (July 2nd, 2024) — Areterna LLC, a company with a mission to democratize mRNA vaccine by supplying low-cost GMP raw materials, today announced plans to offer veterinary mRNA vaccine development service to its customers in the US...
FOR IMMEDIATE RELEASE Areterna LLC, a subsidiary of Synthgene Biotech renowned for providing top-tier raw materials and services catering to mRNA and oligonucleotide therapeutics, has signed a global distribution agreement with BIORON GmbH, a premium manufacturer and...
